医中誌リンクサービス


文献リスト

1)Ikeda Y, Shimada K, Teramoto T, et al. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial. JAMA. 2014; 312: 2510-20
PubMed CrossRef
医中誌リンクサービス
2)Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009; 373: 1849-60
PubMed CrossRef
医中誌リンクサービス
3)Barnett H, Burrill P, Iheanacho I. Donʼt use aspirin for primary prevention of cardiovascular disease. BMJ. 2010; 340: c1805
PubMed CrossRef
医中誌リンクサービス
4)Seshasai SR, Wijesuriya S, Sivakumaran R, et al. Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials. Arch Intern Med. 2012; 172: 209-16
PubMed CrossRef
医中誌リンクサービス
5)(FDA) FaDA. Use of Aspirin for Primary Prevention of Heart Attack and Stroke. http: //wwwfdagov/drugs/resourcesforyou/consumers/ucm390574htm. 2014
医中誌リンクサービス
6)Ogawa H, Nakayama M, Morimoto T, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA. 2008; 300: 2134-41
PubMed CrossRef
医中誌リンクサービス
7)Mauri L, Kereiakes DJ, Yeh RW, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014; 371: 2155-66
PubMed CrossRef
医中誌リンクサービス
8)Feres F, Costa RA, Abizaid A, et al. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. JAMA. 2013; 310: 2510-22
PubMed
医中誌リンクサービス
9)Navarese EP, Andreotti F, Schulze V, et al. Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials. BMJ. 2015; 350: h1618
PubMed CrossRef
医中誌リンクサービス
10)Spencer FA, Prasad M, Vandvik PO, et al. Longer- versus shorter-duration dual-antiplatelet therapy after drug-eluting stent placement: A systematic review and meta-analysis. Ann Intern Med. 2015; 163: 118-26
PubMed CrossRef
医中誌リンクサービス
11)Cassese S, Byrne RA, Tada T, et al. Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drug-eluting stent era: a meta-analysis of randomized trials. Eur Heart J. 2012; 33: 3078-87
PubMed CrossRef
医中誌リンクサービス
12)Bonaca MP, Bhatt DL, Cohen M, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015; 372: 1791-800
PubMed CrossRef
医中誌リンクサービス
13)Lip GY, Windecker S, Huber K, et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J. 2014; 35: 3155-79
PubMed CrossRef
医中誌リンクサービス
14)Dewilde WJ, Oirbans T, Verheugt FW, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet. 2013; 381: 1107-15
PubMed CrossRef
医中誌リンクサービス
15)Capodanno D, Lip GY, Windecker S, et al. Triple antithrombotic therapy in atrial fibrillation patients with acute coronary syndromes or undergoing percutaneous coronary intervention or transcatheter aortic valve replacement. EuroIntervention. 2015; 10: 1015-21
PubMed CrossRef
医中誌リンクサービス
16)Shinohara Y, Katayama Y, Uchiyama S, et al. Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol. 2010; 9: 959-68
PubMed CrossRef
医中誌リンクサービス
17)Uchiyama S, Tanahashi N, Minematsu K, et al. Clopidogrel two doses comparative 1-year assessment of safety and efficacy (COMPASS) study in Japanese patients with ischemic stroke. Cerebrovasc Dis. 2012; 34: 229-39
PubMed CrossRef
医中誌リンクサービス
18)Investigators SPS, Benavente OR, Hart RG, et al. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. N Engl J Med. 2012; 367: 817-25
PubMed CrossRef
医中誌リンクサービス
19)Wallentin L, James S, Storey RF, et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet. 2010; 376: 1320-8
PubMed CrossRef
医中誌リンクサービス
20)Harrington RA, Stone GW, McNulty S, et al. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med. 2009; 361: 2318-29
PubMed CrossRef
医中誌リンクサービス
21)Bhatt DL, Lincoff AM, Gibson CM, et al. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med. 2009; 361: 2330-41
PubMed CrossRef
医中誌リンクサービス


NPO医学中央雑誌刊行会
https://www.jamas.or.jp/
info@jamas.or.jp